# Navan, Inc.

Type: Company (NAVN)

Source: GetYourBrief — https://getyourbrief.com/entity/navan-inc
Canonical HTML page: https://getyourbrief.com/entity/navan-inc

## Timeline

- **2026-Q3**: Motion to Dismiss Phase — Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
- **2026-Q3**: Discovery Phase Begins — Courts likely to rule on motions to dismiss, leading to the exchange of internal corporate documents.
- **2026-04-15**: Lead Plaintiff Deadline — Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.
- **2026-04-15**: Lead Plaintiff Deadline (Est.) — Typical 60-day window for investors to petition the court to lead the consolidated class action.
- **2026-04-15**: Lead Plaintiff Deadline (Estimated) — Expected window for investors to file motions to lead the class actions against RARE, MREO, and NAVAN.
- **2026-03-25**: Q4 2026 Earnings Release — Official release of fiscal year-end financial results and SEC filing.
- **2026-03-25**: Earnings Conference Call — Management discussed AI integration and 2027 guidance with analysts.
- **2026-03-06**: Market Reaction — Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.
- **2026-03-05**: Investor Alerts Issued — Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.
- **2026-03-05**: Investor Alerts Issued — Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector.
- **2026-03-05**: Coordinated Legal Alerts — Pomerantz Law Firm issues a series of reminders for class action deadlines across four major firms.
- **2026-01-28**: Director Election Filing — Navan filed an 8-K regarding the election of new directors to the board.

## Recent coverage (5 stories, network-wide)

### Navan (NAVN) Q4 2026: AI-Driven Expense Growth Signals Shift to Profitability
2026-03-26 06:10:21 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Navan (NAVN) concluded its fiscal 2026 with a Q4 earnings call highlighting the successful scaling of its AI-powered expense management platform. CEO Ariel Cohen and VP of Investor Relations Ryan Burkart detailed the company's progress in capturing global enterprise market share while moving toward GAAP profitability.
Full story: https://getfinancebrief.com/story/navan-navn-q4-2026-earnings-analysis

### Pomerantz Law Firm Issues Securities Class Action Deadlines for Four Firms
2026-03-05 23:21:48 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications.
Full story: https://getfinancebrief.com/story/pomerantz-law-firm-securities-litigation-deadlines-2026

### Pomerantz Law Firm Issues Class Action Deadlines for Major Biotech Firms
2026-03-05 23:21:15 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
Full story: https://getbiobrief.com/story/pomerantz-biotech-class-action-deadlines-2026

### Pomerantz Law Firm Targets Biotech and Tech Sectors in Securities Class Actions
2026-03-05 23:21:10 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.
Full story: https://getlegalbrief.com/story/pomerantz-securities-class-actions-biotech-tech-2026

### Pomerantz Law Firm Launches Multi-Sector Securities Fraud Investigations
2026-02-20 02:48:06 · Sector: finance · Sentiment: Negative · Impact: 6/10 · Sources: 7

Pomerantz Law Firm has initiated a series of investigations into seven companies, including Snowflake and Navan, regarding potential securities fraud and unlawful business practices. These probes target firms across the technology, finance, and healthcare sectors, signaling a heightened period of legal scrutiny for public entities.
Full story: https://getfinancebrief.com/story/pomerantz-law-firm-investigations-snowflake-navan

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.